fda bans compounded semaglutide and tirzepatide Tirzepatide! Now What? FDA alerts health care providers,

In the obesity trial, maximal WL was achieved with retatrutide 12 mg after 48 weeks: -24.2% vs

Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-label

Table of Contents GLP-1 Medications and Surgery: Perioperative Considerations Glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda) are widely prescribed for type 2 diabetes and weight management

2024 Feb;22(2):259-270

GLP-1 receptor agonists and combination therapies have demonstrated benefit in the treatment of obstructive sleep apnoea (OSA), a disease characterised by repetitive episodes of partial or complete upper airway collapse, through the effects of weight lossreduction of upper airway and neck adiposity which can compress the airway and visceral adiposity which can reduce lung volumes [124, 125]

It is estimated that by 2045 there will be 693 million people diagnosed with the condition worldwide [1]